FORMYCON AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.7 EUR | +0.41% |
|
-0.31% | -13.65% |
| Apr. 25 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 319 | 530 | 651.7 | 1,309 | 904.6 | 860 | - | - |
| Enterprise Value (EV) 1 | 296.6 | 487.8 | 626.6 | 1,648 | 904.6 | 850.5 | 850.9 | 790.3 |
| P/E ratio | -139 x | -98.4 x | -48.4 x | 33.4 x | 11.9 x | -52.4 x | -785 x | 11 x |
| Yield | - | - | - | - | - | - | 0.5% | - |
| Capitalization / Revenue | 9.41 x | 15.5 x | 17.6 x | 30.8 x | 11.6 x | 14.4 x | 10.6 x | 4.77 x |
| EV / Revenue | 8.75 x | 14.3 x | 17 x | 38.8 x | 11.6 x | 14.2 x | 10.4 x | 4.39 x |
| EV / EBITDA | -212 x | -101 x | -50.6 x | -104 x | 596 x | -46.3 x | 79.4 x | 7.7 x |
| EV / FCF | -123 x | -86.1 x | -42.1 x | -36.1 x | - | -10.1 x | -35.8 x | 15.1 x |
| FCF Yield | -0.81% | -1.16% | -2.38% | -2.77% | - | -9.86% | -2.8% | 6.63% |
| Price to Book | 6.62 x | 8.57 x | 11.6 x | 3.67 x | - | 1.8 x | 1.78 x | 1.53 x |
| Nbr of stocks (in thousands) | 10,000 | 10,000 | 11,047 | 15,130 | 16,039 | 17,660 | - | - |
| Reference price 2 | 31.90 | 53.00 | 59.00 | 86.50 | 56.40 | 48.70 | 48.70 | 48.70 |
| Announcement Date | 5/18/20 | 5/17/21 | 5/18/22 | 4/27/23 | 4/25/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 33.9 | 34.23 | 36.96 | 42.5 | 77.7 | 59.69 | 81.44 | 180.1 |
| EBITDA 1 | -1.4 | -4.81 | -12.39 | -15.87 | 1.518 | -18.36 | 10.72 | 102.6 |
| EBIT 1 | -2.3 | -5.725 | -13.33 | -17.73 | -0.369 | -23.11 | -10.41 | 85.58 |
| Operating Margin | -6.78% | -16.73% | -36.07% | -41.72% | -0.47% | -38.73% | -12.79% | 47.51% |
| Earnings before Tax (EBT) 1 | -2.291 | -5.923 | -13.47 | 36.6 | 79.07 | -12.39 | 2.829 | 103 |
| Net income 1 | -2.293 | -5.926 | -13.48 | 35.99 | 75.8 | -15.36 | 0.9286 | 80.65 |
| Net margin | -6.76% | -17.31% | -36.46% | 84.69% | 97.55% | -25.73% | 1.14% | 44.77% |
| EPS 2 | -0.2293 | -0.5387 | -1.218 | 2.590 | 4.720 | -0.9300 | -0.0620 | 4.436 |
| Free Cash Flow 1 | -2.403 | -5.662 | -14.88 | -45.64 | - | -83.87 | -23.8 | 52.4 |
| FCF margin | -7.09% | -16.54% | -40.26% | -107.39% | - | -140.51% | -29.22% | 29.09% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 51.06% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 64.97% |
| Dividend per Share 2 | - | - | - | - | - | - | 0.2433 | - |
| Announcement Date | 5/18/20 | 5/17/21 | 5/18/22 | 4/27/23 | 4/25/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 17.7 | 14 | 14 | 14 | 17 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -6 | -5.4 | -5.4 | -5.4 | - |
| Operating Margin | - | -33.9% | -38.57% | -38.57% | -38.57% | - |
| Earnings before Tax (EBT) 1 | - | -6 | -4.95 | -4.95 | -4.95 | - |
| Net income 1 | 1.804 | -6 | -4.95 | -4.95 | -4.95 | - |
| Net margin | - | -33.9% | -35.36% | -35.36% | -35.36% | - |
| EPS 2 | 0.1130 | -0.3700 | -0.2900 | -0.2800 | -0.2800 | -0.2000 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/30/23 | - | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 339 | - | - | - | - |
| Net Cash position 1 | 22.4 | 42.2 | 25.2 | - | - | 9.53 | 9.12 | 69.7 |
| Leverage (Debt/EBITDA) | - | - | - | -21.36 x | - | - | - | - |
| Free Cash Flow 1 | -2.4 | -5.66 | -14.9 | -45.6 | - | -83.9 | -23.8 | 52.4 |
| ROE (net income / shareholders' equity) | -5.63% | -10.2% | -21.7% | 17.5% | - | -2.9% | 0.2% | 11.7% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 4.820 | 6.190 | 5.070 | 23.60 | - | 27.00 | 27.30 | 31.70 |
| Cash Flow per Share 2 | - | -0.4600 | -1.280 | -1.380 | - | -1.520 | 1.740 | 5.990 |
| Capex 1 | 0.92 | 0.56 | 0.7 | 26.8 | - | 60.1 | 55 | 54.7 |
| Capex / Sales | 2.72% | 1.63% | 1.9% | 62.97% | - | 100.74% | 67.47% | 30.35% |
| Announcement Date | 5/18/20 | 5/17/21 | 5/18/22 | 4/27/23 | 4/25/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
48.7
EUR
Average target price
86.25
EUR
Spread / Average Target
+77.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.65% | 933M | |
| +48.54% | 56.61B | |
| +37.15% | 39.25B | |
| -6.02% | 39.62B | |
| -6.90% | 28.28B | |
| +12.97% | 26.44B | |
| -16.91% | 20.12B | |
| +31.71% | 12.48B | |
| +28.18% | 12.51B | |
| +0.38% | 12.2B |
- Stock Market
- Equities
- FYB Stock
- Financials Formycon AG
